DUBLIN–(BUSINESS WIRE)–The “Influenza A Virus, H1N1 Subtype Infections – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This latest pipeline guide provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews the key players involved in the therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 7, 9, 4, 43, 7 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 4, 2, 13 and 2 molecules, respectively.
Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1.
- The guide reviews pipeline therapeutics by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H1N1 therapeutics based on mechanism of action (MoA), drug target, route of administration and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1
Key benefits:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Influenza A Virus, H1N1 Subtype Infections – Overview
- Influenza A Virus, H1N1 Subtype Infections – Therapeutics Development
- Influenza A Virus, H1N1 Subtype Infections – Therapeutics Assessment
- Influenza A Virus, H1N1 Subtype Infections – Companies Involved in Therapeutics Development
- Influenza A Virus, H1N1 Subtype Infections – Drug Profiles
- Influenza A Virus, H1N1 Subtype Infections – Dormant Projects
- Influenza A Virus, H1N1 Subtype Infections – Discontinued Products
- Influenza A Virus, H1N1 Subtype Infections – Product Development Milestones
- Appendix
Companies Mentioned
- AbbVie Inc
- Abzyme Therapeutics LLC
- Adimmune Corp
- Akshaya Bio Inc
- Alla Chem LLC
- Allergy Therapeutics Plc
- Altimmune Inc
- Ansun Biopharma Inc
- Asavi Llc
- AstraZeneca Plc
- Beijing Minhai Biotechnology Co Ltd
- BlueWillow Biologics Inc
- Brandenburg Antiinfektiva GmbH
- BunyaVax BV
- CEL-SCI Corp
- Changchun Bcht Biotechnology Co Ltd
- Chicago Biosolutions Inc
- EpiVax Inc
- Etubics Corp
- FluGen Inc
- Gamma Vaccines Pty Ltd
- Genentech Inc
- GlaxoSmithKline Plc
- Greffex Inc
- i2 Pharmaceuticals Inc
- ILiAD Biotechnologies LLC
- Imutex Ltd
- Johnson & Johnson
- Mayly Life Sciences
- Medicago Inc
- Microbiotix Inc
- NanoViricides Inc
- New Amsterdam Sciences Inc
- Novavax Inc
- PeptiDream Inc
- Pneumagen Ltd
- Recce Ltd
- Sanofi Pasteur SA
- Sciogen Inc
- Vaccibody AS
- Vacthera BioTech GmbH
- Vaxart Inc
- Vaxxas Pty Ltd
- Viramatix Sdn Bhd
- Virion Biotherapeutics
- Vironova Medical AB
- Virvio Inc
- Visterra Inc
- Vivaldi Biosciences Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/wlda6e.
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
